Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AROMA: Long-term outcomes of Dupixent in chronic rhinosinusitis with nasal polyps
jRCT1031210642Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Baseline Patient Characteristics and Baseline Disease Characteristics. Started Aug 2021; status: active, not recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on jRCT1031210642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210642.